CATALYSTBenzinga • 1d ago
Why Is Apimeds Pharmaceuticals Stock Gaining Monday?Benzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
Why APUS Stock dropped -3.99% Today — RQD Quant Desk Flash
$2.89 -3.99% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.86
Apimeds Pharmaceuticals US Inc. (APUS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $4.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on APUS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.89 (-3.99% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APUS ranks #552 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does APUS compare to AZTR and TRAW in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.2%. By comparison, AZTR (Azitra Inc) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for APUS?
▼
Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $33.4M in revenue (+834.2% YoY), -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.86 (-0.91%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-9.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APUS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY APUS SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.62-26.2% Next Q
45
Q2 (-2Q)Grade D$3.41-10.6% Next Q
42
Q3 (-1Q)Grade D$3.05-5.2% Next Q
40
CurrentGrade D-$2.89-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a APUS Turnaround Squeeze
While APUS currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.03) forces dealer call-delta covering toward $62.69.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $APUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “APUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why APUS Stock dropped -3.99% Today — RQD Quant Desk Flash
Apimeds Pharmaceuticals US Inc. (APUS) dropped -3.99% to $2.89, trading at 2% of its 52-week range ($1.51 – $59.7). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.51 – $59.7) with RSI-14 at 42.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.89 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live APUS Headlines & Catalysts
CATALYSTkalkine.ca • 1d ago
Why Did Apimeds (NYSEAMERICAN:APUS) Jump 55.3% After 42.5%?kalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETimothy Sykes • 1d ago
APUS Stock Whipsaws As Traders Target Extreme VolatilityTimothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Apimeds Pharmaceuticals US (NYSEAM:APUS) - Stock AnalysisSimply Wall St report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session - Apimeds Pharmaceuticals (AMEX:APUS), OptionBenzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStocksToTrade • 1d ago
APUS Stock Whipsaws As Traders Zero In On Volatility And Cash BurnStocksToTrade report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETimothy Sykes • 1d ago
APUS Stock Whipsaws After Huge Run, Drawing Day TradersTimothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Why Is Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) Up 8.29% Pre-Market on Tuesday? The Catalyst, the Fundamentals and What Comes Nextkalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APUS)
- ✓Walkthrough of APUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
APUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.21H $3.21L $2.89C $2.89VOL 21.5K
RES: $12.46SUP: $-1.30SMA50: $3.63SMA200: $10.76
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
APUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +834.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on APUS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for APUS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APUS)
Health Care Rank #552 of 1015
⚔️ AZTR vs APUS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (APUS vs. AZTR, TRAW, XBIO, CANF)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Apimeds Pharmaceuticals US Inc. (APUS) ranks #552 by composite RQD confidence (37/100, grade D-) and #951 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, APUS leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. APUS currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APUS
ACTIVE
Apimeds Pharmaceuticals US Inc. | D- | 37/100 | — | — | -6.2% | -3.99% | $4.6M | Benchmark Subject |
| AZTR Azitra Inc | E | 33/100 | — | — | -35.0% | +8.72% | $4.7M | /aztr-vs-apus → |
| TRAW Traws Pharma Inc. | E | 31/100 | — | — | -35.0% | +1.45% | $4.5M | /traw-vs-apus → |
| XBIO Xenetic Biosciences Inc. | E | 32/100 | — | — | -30.3% | +0.49% | $4.8M | /xbio-vs-apus → |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 25/100 | — | — | -35.0% | +0.62% | $4.9M | /canf-vs-apus → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894525 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported GAAP revenue of $33.4M (+834.2% vs. FY2024 revenue of $3.6M , and +1493.8% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-1124.6% YoY). On the balance sheet, APUS closed FY2025 with $164.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.4M | -$6.0M | -$8.9M | -$9.0M | $164.2M | — |
| FY2024 (FY) | 2024-12-31 | $3.6M | -$1.4M | -$733.5K | -$733.5K | $13.1K | — |
| FY2023 (FY) | 2023-12-31 | $2.1M | -$777.7K | -$627.8K | -$627.8K | — | — |
3. APUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.89 (-3.99% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APUS ranks #552 in composite RQD confidence.
How does APUS compare to AZTR and TRAW in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.2%. By comparison, AZTR (Azitra Inc) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for APUS?
Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $33.4M in revenue (+834.2% YoY), -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is APUS trading relative to its 50-day, 200-day, and 52-week technical levels?
APUS last traded at $2.89 (-3.99% on volume of 38,452 shares), positioning the stock -20.39% below its 50-day simple moving average ($3.63) and -73.14% below its 200-day simple moving average ($10.76). Across its 52-week range of $1.51 to $59.70, APUS sits at the 2.4% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.53 to $3.25).
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ SEC XBRL & RQD VERIFIED
APUS — Apimeds Pharmaceuticals US Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Apimeds Pharmaceuticals US Inc. (APUS) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.89 (-3.99% 1D, market capitalization $4.6M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -6.2%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Apimeds Pharmaceuticals US Inc. Is listed on the NYSE and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.0B on a rounded basis, which conflicts with the $5.0M figure in market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported $33.4M in annual revenue (up from $3.6M in FY2024, +834.2% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.1M revenue, -$777.7K net income) through FY2025, APUS scaled operating cash flow to -$8.9M and free cash flow to -$9.0M, backed by $164.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.51 – $59.70 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), APUS carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can APUS sustain or expand its — operating margin and -6.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $33.4M and free cash flow of -$9.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is APUS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
APUS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Apimeds Pharmaceuticals US Inc. (APUS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Benzinga • 1d ago
Why Is Apimeds Pharmaceuticals Stock Gaining Monday? Benzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 1d ago
Why Did Apimeds (NYSEAMERICAN:APUS) Jump 55.3% After 42.5%? kalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Timothy Sykes • 1d ago
APUS Stock Whipsaws As Traders Target Extreme Volatility Timothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Apimeds Pharmaceuticals US (NYSEAM:APUS) - Stock Analysis Simply Wall St report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session - Apimeds Pharmaceuticals (AMEX:APUS), Option Benzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StocksToTrade • 1d ago
APUS Stock Whipsaws As Traders Zero In On Volatility And Cash Burn StocksToTrade report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Timothy Sykes • 1d ago
APUS Stock Whipsaws After Huge Run, Drawing Day Traders Timothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Why Is Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) Up 8.29% Pre-Market on Tuesday? The Catalyst, the Fundamentals and What Comes Next kalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
APUS Bull vs. Bear Conversation Board — What's Your Call at $2.89?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APUS 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $3.67 (+21.9%)
📌 Pinned Debate The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum t
Picked up a starter position in APUS in my $100K Virtual Cash book at $3.01. The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum traders.. Trading inside a $1.51–$59.70 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
RetailWhale_TX 🐂 BULL
Both sides have a point here — APUS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $2.56 (-15.0%)
Spot @ $3.01 With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity t
Fading this rally in APUS at $3.01. With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity to fund operations without new capital.. With a beta of 1.0 and the stock sitting at $3.01 (52-wk range $1.51–$59.70), the easy multiple expansion is already priced in.